U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07033858) titled 'Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation' on May 27.
Brief Summary: Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf(R)/Astagraf XL(R), Astellas company).
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Kidney Transplant; Complications
Intervention:
DRUG: Rapamune Pill
Rapamiune Tablet 1mg daily plus Advograf plus prednisolone...